Loading...
Market
Eli Lilly Stock Up 10% Post FDA Approval?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from sources like Yahoo Finance or Bloomberg
Story
FDA Panel Unanimously Backs Eli Lilly's Alzheimer's Drug Donanemab in 11-0 Vote
Jun 10, 2024, 07:47 PM
Eli Lilly's experimental Alzheimer's drug, donanemab, has received unanimous backing from an FDA advisory panel. The panel voted 11-0 in favor of the drug's efficacy, stating that its benefits outweigh the risks, despite concerns about brain bleeding and swelling, particularly in APOE4 carriers. This recommendation paves the way for potential full approval of donanemab in the United States later this year. The drug was shown to significantly slow clinical progression of Alzheimer's disease in the TRAILBLAZER-ALZ 2 trial, which was published in JAMA. The panel also reviewed safety risks and the design of clinical trials. Eli Lilly's shares rose 2% following the panel's vote.
View original story
Similar markets
Yes • 50%
No • 50%
Increase by 5% or more • 50%
Increase by less than 5% or decrease • 50%
Yes • 50%
No • 50%
Significant stock price increase (over 15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (0-5%) • 25%
Stock price decrease • 25%
Significant stock price increase (>15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (<5%) • 25%
Stock price decrease • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
No significant change • 25%
Decrease • 25%